Background-Recent exome sequencing studies identified filamin C (FLNC) as a candidate gene for hypertrophic cardiomyopathy (HCM). Our aim was to determine the rate of FLNC candidate variants in a large cohort of HCM patients who were also sequenced for the main sarcomere genes. Methods and Results-A total of 448 HCM patients were next generation-sequenced (semiconductor chip technology) for the MYH7, MYBPC3, TNNT2, TNNI3, ACTC1, TNNC1, MYL2, MYL3, TPM1, and FLNC genes. We also sequenced 450 healthy controls from the same population. Based on the reported population frequencies, bioinformatic criteria, and familial segregation, we identified 20 FLNC candidate variants (13 new; 1 nonsense; and 19 missense) in 22 patients. Compared with the patients, only 1 of the control's missense variants was nonreported (P=0.007; Fisher exact probability test). Based on the familial segregation and the reported functional studies, 6 of the candidate variants (in 7 patients) were finally classified as likely pathogenic, 10 as variants of uncertain significance, and 4 as likely benign. Conclusions-We provide a compelling evidence of the involvement of FLNC in the development of HCM. Most of the FLNC variants were associated with mild forms of HCM and a reduced penetrance, with few affected in the families to confirm the segregation. Our work, together with others who found FLNC variants among patients with dilated and restrictive cardiomyopathies, pointed to this gene as an important cause of structural cardiomyopathies.
Hypertrophic cardiomyopathy (HCM) is the most common genetic myocardial disease. In approximately half of the patients, the disease is linked to variants in well characterized sarcomere protein genes, with MYH7 (cardiac β-myosin heavy chain) and MYBPC3 (cardiac myosin-binding protein C) accounting for most of the variants. 1, 2 Next-generation sequencing (NGS) techniques facilitate the screening of the HCM genes in large cohorts of patients. 3 In spite of this advance, causative variants are not identified in a significant number of patients who may, thus, harbor pathogenic variants in new HCM genes. Using an exome sequencing approach, our group identified the filamin C (FLNC) as a candidate HCM gene. 4 A putative FLNC variant (c.C4824G, p.A1539T) segregated with the disease in a family with several HCMaffected individuals, otherwise negative for the known HCM genes. Moreover, a complete FLNC sequencing in 92 HCM cases identified 7 additional variants, which segregated with the disease in their families. Heart tissue studies in some of these patients showed marked sarcomeric abnormalities in cardiac muscle, and functional analysis in cell cultures revealed that expression of the FLNC variants resulted in the formation of large FLNC aggregates. 4 More recently, variants in FLNC have been found in dilated cardiomyopathy and restrictive cardiomyopathy (RCM) patients, suggesting an important role of FLNC in the development of cardiomyopathies. 5, 6 See Clinical Perspective FLNC encodes filamin C, a protein involved in muscle function by interacting with proteins of the sarcolemma and the Z disc. 7, 8 Although this protein is expressed in skeletal and heart muscle, FLNC variants had been associated to myofibrillar myopathy, with some of these patients also showing cardiomyopathy. [9] [10] [11] [12] Interestingly, none of our HCM patients showed symptoms of myopathy, and the analysis of skeletal muscle biopsies from 2 of them showed a normal muscle fiber histology and biochemistry. 4 These findings suggest that FLNC variants are not restricted to skeletal muscle disorders, but can also generate cardiac muscle abnormalities without skeletal myopathy.
Our aim was to determine the mutational spectrum of FLNC in a large cohort of HCM patients to establish the FLNC in Hypertrophic Cardiomyopathy genetic contribution of this gene to HCM and the correlate of FLNC variants with the phenotype.
Methods

Patient and Control Cohorts
This research was approved by the Ethical Committee of Hospital Universitario Central Asturias, and all the participants signed an informed consent. A total of 448 HCM nonrelated index cases were recruited through the Hospital Universitario Central Asturias-Reference Unit for Familial Cardiomyopathies in the period 2001 to 2015. HCM was diagnosed based on clinical symptoms and a left ventricular septum ≥15 mm in the absence of any other condition that could explain the hypertrophy. Clinical evaluation included medical history, physical examination, 12-lead EKG, M-mode, 2-dimensional, and Doppler echocardiography. Some patients have also records of cardiac magnetic resonance, pacemaker reports, 24-hour Holter monitoring EKG, or exercise test. The sudden cardiac death risk score was calculated according to the 2014 Guidelines in high risk of sudden cardiac death. 13 Patients with at least 1 known relative who had been also diagnosed with HCM were defined as familial cases. In patients who carried candidate variants, we performed echocardiography to all the relatives who agreed to participate to determine the left ventricular septum.
We sequenced the FLNC gene in a total of 450 individuals of the Renal Health in Asturias (RENASTUR) cohort. They were Whites aged 60 to 85 years and without symptom of HCM. The main characteristics of this cohort was reported elsewhere. All the patients were sequenced for the MYH7, MYBPC3, TNNT2,  TNNI3, ACTC1, TNNC1, MYL2, MYL3, TPM1 , and FLNC genes using NGS with a custom AmpliSeq gene panel and the Ion Torrent Personal Genome Machine (PGM) semiconductor chip technology (Thermo Fisher Scientific). The AmpliSeq panel was designated online (Ion AmpliSeq Designer v4; https://www.ampliseq.com) to cover the coding exons plus at least 5 intron flanking nucleotides of the 10 genes. We compared several primer design options and ordered the one that gave the maximum target sequence coverage. Primer pairs to amplify a total of 255 fragments that covered 98.2% of the target sequence were provided by the manufacturer in only 2 tubes (Table I in the Data Supplement).
14,15
Next-Generation Sequencing
The NGS procedure was previously validated and described in detail as supplementary file. 3, 16 Briefly, DNA from each patient was obtained and adjusted to a final concentration of 10 ng/μL. DNA pools containing 10 μL of the corresponding DNAs were prepared. The number of samples used to create the pools was decided taking into account the load capacity of the chip, the total length of the target sequences (≈46 Kb), the dilution of a unique rare allele inside the pool, and the number of reads per amplicon necessary to achieve a minimum coverage of 50×. Each pool was amplified with the Ion AmpliSeq Library Kit 2.0 in conjunction with Ion AmpliSeq Custom Primer Pool protocols according to the manufacturer's procedures (Thermo Fisher Scientific) and following the next steps: polymerase chain reaction (PCR) in 2 tubes, partial digestion of the primers with FuPa Reagent, ligation of the bar code adapters, purification by Agencourt AMPure XP Reagent, PCR with the adapters using Platinum PCR SuperMix High Fidelity enzyme (Invitrogen), purification by Agencourt AMPure XP Reagent, quantification of the sample (Agilent Bioanalyser Tapestation 2200 and Qubit 2.0 Fluorometer), and dilution of the sample to a final concentration of 8 pmol/L.
After amplification, emulsion PCR and enrichment were performed using Ion OneTouch 2 instrument and Ion ES instrument following the manufacturer's instructions (Thermo Fisher Scientific). We performed an emulsion PCR using the Ion PGM template Hi-Q OT2 Kit in the Ion OneTouch 2 instrument (Thermo Fisher Scientific). Template-positive spheres were recovered using Dynabeads MyOne Streptavidin C1 beads in the ES instrument (Thermo Fisher Scientific).
The sequencing was performed in the Ion Torrent Personal Machine Sequencer (PGM) using the Ion PGM Hi-Q sequencing Kit, with 318-v2 semiconductor chips. We used a 500-flow runs, which support a template read length of ≈200 bp. The raw PGM data were processed with the Torrent Suite v5 software (Thermo Fisher Scientific) to generate sequence reads filtered by the pipeline software quality controls. Reads assembling and variant identification were performed using both Variant Caller v5 software and Ion Reporter v5 software, using FastQ files containing sequence reads and the Ion AmpliSeq Designer BED file software to map the amplicons. We used the Integrative Genome Viewer (Broad Institute) for the analysis of depth coverage, sequence quality, and variants identification. Variants were identified with the somatic sample default algorithm.
The raw data were aligned against the reference GRCh38 sequence. Because Exome Aggregation Consotium (ExAC) variants are numbered according to the GRCh37 (hg19) sequence, to facilitate the interpretation of the genetic variation by other research groups, we referred the nucleotide position relative to the GRCh37. In reference to the coding sequence, the nucleotides were numbered according to the Emsembl (www.ensembl.org) FLNC transcript, ENST00000325888 (NM_001458).
For each candidate variant identified in the pools, the corresponding DNAs were individually amplified and sequenced with BigDye chemistry in an ABI3130 equipment (Life Technologies) to identify the carriers.
Variants Classification
Nucleotide variants that result in frameshift changes or likely affected mRNA splicing (changes in the intron splicing consensus nucleotides) were classified as probably damaging. Nonsense missense amino acid changes either not present among the controls or in less than 3 exomes in the Exome Sequencing Project (ESP) database were also classified as candidate variants for segregation studies; otherwise, FLNC variants were considered as polymorphism. The potential effect of these variants was measured by in silico predictors Poly-phen2 17 and SIFT 18 and meta-predictors Condel 19 and CADD. 20 Candidate variants were initially classified as follows: those with a positive segregation in at least 3 HCM affected in the family were classified as likely pathogenic; those with a positive segregation in only 2 patients but disease-associated by functional studies were also classified as likely pathogenic; otherwise, were classified as of uncertain significance (variant of uncertain effect) or likely benign variants (Figure 1 ). The variants were also classified according to the American College of Medical Genetics and Genomics criteria for variant classification in nonvalidated genes, as was the case of FLNC in HCM. 21 
Results
FLNC Variants in HCM Patients and Controls
A total of 169 of the 448 patients (38%) were carriers of variants in the main HCM-related genes (MYH7, MYBPC3, TNNT2, TNNI3, ACTC1, TNNC1, MYL2, MYL3, TPM1; Table II in the Data Supplement). In reference to FLNC, 46 of the 48 exons (96%) gave optimal reads in the NGS, and only exons 3 and 29 were below a 50× coverage ( Figure I in the Data Supplement). Because these sequence failures were replicated in all the PGM runs, we concluded that the absence of nucleotide reads was likely because of some characteristic that made them refractory to amplification (such as a high GC nucleotide content), and exons 3 and 29 were, thus, Sanger sequenced in all patients. Nine of the rare FLNC variants had been previously characterized, and all these nucleotide changes were also identified in the NGS ( Figure II in the Data Supplement). We, thus, concluded that our semiconductor chip NGS approach was highly effective in the screening of FLNC.
Among the HCM patients, we found a total of 37 missense and 1 nonsense variant (Table 1) . We performed the NGS with the same gene panel in 450 healthy elderly individuals, and we found a total of 22 missense variants ( Table 2) . We compared the frequency of variants found only in controls (n=9; 2%) versus only in patients (n=25; 5.6%), and the difference was significant; P=0.005. Only 1 of the control missense variants (c.5813C>T, p.P1938L) was not reported in both ESP and ExAC databases compared with 13 of the variants in the patients. Thus, the frequency of carriers of nonreported missense FLNC variants was 0.2% in the controls (1/450) versus 3.1% (14/448) in the patients (P=0.007; Fisher exact probability test). We could perform an echocardiography in the controls with 9 rare variants (including the p.P1938L carrier), and all of them presented septa in the normal range, which was consistent with the absence of HCM symptoms and nonpathogenic effect.
FLNC Variants Classification
A total of 20 FLNC nucleotide changes in 22 patients passed our basic criteria for candidate variants and were further subjected to familial screening ( Figure 2 ). To our knowledge, none of the 20 FLNC variants have been found in patients with myopathy.
They were missense (n=19) or nonsense (n=1, p.E108X), absent in our control cohort, or reported at low frequency in the exome project database (Table 1) . Among the 20 variants, 13 were new, 5 were rare nucleotide changes only in the ExAC, and only 2 in both ESP and ExAC databases. A total of 6 of the candidate variants were finally classified as likely pathogenic based on the familial segregation or positive functional studies: p.V123A, p.A1539T (2 patients), p.R2133H, p.R2140Q, p.P2298S, p.H2315N. Ten and 4 variants were classified as variant of uncertain effect and likely benign, respectively.
Four of the FLNC carriers also had a variant in the MYH7 or MYBPC3 genes. Thus, the frequency of FLNC rare variants was higher among noncarriers of a variant in the 9 sarcomere genes (18/279=6.4% versus 4/169=2.3%; P=0.03, Fisher exact probability test).
Family Studies
We could perform family studies in 15 of the 20 FLNC candidate variant carriers ( Figure 3 ). Among these families, 4 were also positive for sarcomere variants. At least a second HCM affected was available for the genetic testing in 11 of the sarcomere-negative patients, and all them were also FLNC variant carriers (Table III in the Data Supplement) . In these families, we identified a total of 36 candidate variant carriers, and 27 of them had hypertrophic left ventricular septa (excluding the individuals with borderline septum sizes; Table 3; Table  IV in the Data Supplement). Thus, the FLNC candidate variants would lead to incomplete penetrance. Besides, 4 of the 6 nonaffected FLNC carriers were <40 years old, and we cannot exclude a late development of HCM in these individuals. Noteworthy, none of the HCM-affected relatives were negative for the corresponding FLNC variant.
Regarding the 4 carriers of an FLNC plus MYBPC3 or MYH7 variants, only MYH7 p.R143Q in patient 479 was a bona fide pathogenic variant. Two children of this index case were screened for this and the corresponding FLNC variant (p.L1690F), resulting both negative for the MYH7 variant, and a 6-year-old boy had the FLNC variant but a normal echocardiogram ( Figure 3) . Thus, the pathogenicity of this FLNC variant could not be confirmed by family studies and was, thus, classified as of uncertain effect. We could perform family studies in the index case with MYBPC3 p.G1248R+FLNC p.E1408D. Despite the fact that several relatives were carriers of one or both variants, only the index case manifested HCM, and this questioned the pathogenicity of the 2 variants; FLNC p.E1408D was, thus, classified as a likely benign variant. The third index case was MYH7 p.R1689H+FLNC p.N1843S, and no family members were available for the clinical and genetic study. Because of this limitation and the bioinformatic prediction, we classified this FLNC variant as likely nonpathogenic. The latter case was MYBPC3 p.E258K+FLNC p.R2045Q. This MYBPC3 variant was previously linked to HCM in several cohorts but present also in 3 individuals of the ExAC database. We could study 2 
Characteristics of Patients With FLNC Candidate Variants
Based on population frequencies, bioinformatic prediction, functional studies, and the familial segregation, a total of 6 variants were considered as likely pathogenic, 10 as of uncertain significance, and 4 as likely benign (Table 1) . However, considering the American College of Medical Genetics and Genomics criteria for variant classification, only p.V123A and p.A1539T remained as likely pathogenic, the other variants being classified as variant of uncertain effect. The main characteristics of the HCM index cases with FLNC candidate variants are summarized in Table 3 . Most of the patients had mild symptoms, and this nonsevere clinical course would result in a reduced penetrance, which was in agreement with the lack of a large family history of HCM in most of the patients. Only 5 patients had a known family history of the disease (at least 1 known HCM-relative) at the time of their inclusion in the study. The mean onset age was 38 years (±12, range 20-64), and as presenting symptoms, 8 patients had dyspnea, 3 had syncope, and 3 had chest pain. The mean left ventricular wall thickness was 18.6 mm (±5, range . None of the patients had suffered resuscitated cardiac arrest, and 2 patients had received an ICD implanted for primary prevention, although only 1 of them had a high sudden cardiac death risk according to the 2014 Guidelines in high risk of sudden cardiac death. A patient with an initial diagnosis of HCM evolved to RCM and heart failure with transplant requirement. We compared the main characteristics of the patients with sarcomere and FLNC possibly/likely pathogenic variants, and none of the variables differed (1-way analysis of variance or Fisher exact probability tests) between the 2 groups (Table 4) .
In Table 5 , we summarized the mutational screening of the 9 sarcomere and the FLNC genes in our cohort of HCM patients. Interestingly, 4 of the 6 variants classified as likely pathogenic mapped in exons 39 and 41, near to the C-terminal domain, a fact that points to an important role for this FLNC region in the development of cardiac hypertrophy (P<0.001; χ 2 test; Figure 2 ).
Discussion
We performed a screening of FLNC in a cohort of 448 HCM patients and 450 healthy controls. In a previous analysis of 93 patients, we found 7 unique nonsense or missense variants, nonreported in the human genome variation databases. Here, we found a total of 38 missense/nonsense variants, and 20 were initially selected as candidate variants for family studies screening based on their absence or low frequency among controls. Four of the FLNC candidate variants were in patients who also carried an MYBPC3 or MYH7 variant. The candidate variants were analyzed with several online tools. The in silico predictors can be used to measure the potential pathogenicity of missense variants, although the sensitivity and specificity is low, and this limits its usefulness as clinical tools. 22 Ultimately, the effect of these variants on disease risk should be confirmed by family segregation, which requires a minimum number of affected individuals to obtain a significant logarithm of odds (LOD) score. The highest LOD value After including the bioinformatic prediction, reported functional studies, and the familial data, we found a total of 6 likely pathogenic variants. Ten variants were finally classified as of uncertain significance and 4 as likely benign. Our threshold to define the likely pathogenicity was either the cosegregation in at least 3 HCM affected or a positive segregation in 2 HCMaffected plus functional studies that showed a pathogenic effect. These do not fully address the American College of Medical Genetics and Genomics requirements to classify a variant as definitely pathogenic. 21 These criteria have been established for well-characterized genes with large amount of data to conclude their role in the disease, which it is not yet the case of FLNC in HCM. 21 Under the American College of Medical Genetics and Genomics rules, only p.A1539T and p.V123A fulfill the criteria to be classified as likely pathogenic. The missense changes, p.R2133H, p.R2140Q, p.P2298S, and p.H2315N, did not accomplish these criteria, but either previous studies suggested a functional effect or had a positive segregation of at least 3 HCM affected and were, thus, considered as likely pathogenic. In our cohort, the main limitation to classify the candidate variants was the small size of the families, with segregation across few meiosis to derive significant linkage values. In the absence of a clear familial segregation of the candidate variant with the disease, we cannot rule out that some of the rare amino acid changes are actually neutral, not related with the risk of developing HCM, and were, thus, classified as variant of uncertain effect. 23, 24 This was likely a consequence of the 
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mild phenotype associated with most of the candidate variants, which could result in a reduced penetrance and a lack of large families to confirm the segregation. This is also a characteristic of some of the rare variants in well-characterized HCM genes, which were initially classified as disease-associated variants based on their absence in control cohorts of limited size and by bioinformatic predictors, but are now present in the exome databases. [25] [26] [27] [28] In HCM, the age-dependent penetrance that characterizes most of the candidate variants makes difficult their confirmation by familial linkage analysis. For instance, the MYBPC3 p.G263X is the most common sarcomere mutation in our population. A total of 11 patients (2%) were carriers of this variant, compared with none of the controls. In spite of its clear pathogenic value, this nonsense change was associated with mild forms of HCM, with some carriers remaining asymptomatic at elderly age. 29 As a consequence, we did not identify a second affected relative in 30% of the MYBPC3 p.G263X index cases, who were, thus, apparently sporadic. In the case of FLNC, none of the candidate variants was found in >2 patients, and because of the benign course of HCM in most of the carriers, the private variants (found in only 1 patient) might be difficult to classify based on familial segregation.
Despite the uncertainty that characterizes most of the FLNC candidate variants, several data support a role for this gene in HCM. First, although in some of the families, there were carriers of the candidate variant who did not manifest the disease, none of the affected were negative for the corresponding candidate variant. Second, the frequency of nonreported missense changes was higher in the HCM compared with that in the healthy population cohorts. Only 1 of our control missense variants was not reported in the exome databases, compared with 13 of the HCM variants. Third, the frequency of FLNC carriers was lower among patients with a variant in any of the 9 well-characterized sarcomere genes compared with patients without variants in these genes (2.3% versus 6.4%; P=0.03). If FLNC variants were not associated with HCM, it would be expected a similar frequency of rare variants between the sarcomere-positive and -negative groups.
Variants in FLNC were previously reported in patients with myofibrillar myopathy, with some cases also showing cardiomyopathy. [9] [10] [11] [12] Interestingly, none of the variants associated to myopathy overlapped with those found in our patients, who otherwise showed HCM without signs of myopathy. This suggests that the site of the amino acid change may determine in part the clinical manifestation, either myopathy or a pure cardiomyopathy without skeletal muscle disease. Similar results have been reported for other cardiomyopathy genes, such as DES, LDB3, BAG3, and FHL1, in which the variants resulted in pure or mixed heart and muscle affection. [30] [31] [32] [33] [34] [35] Moreover, recent studies have linked FLNC candidate variants with structural cardiomyopathies in the absence of myofibrillary myopathy. 5, 36, 37 Interestingly, 4 of the 6 FLNC likely pathogenic variants mapped to 2 exons, 39 and 41. On the other hand, the only rare missense variant that mapped to this region in the controls was classified as a polymorphism. These exons contain 41 and 90 amino acids, respectively, that represent 3.3% of the protein sequence. It, thus, seems that amino acid changes at the last immunoglobulin-like rod domains of FLNC are important for the development of HCM and other cardiomyopathies, while none of the myofibrillar myopathy-associated variants are in this protein region. Moreover, we reported that an HCM variant that mapped to this region (p.R2133H) formed FLNC aggregates. 4 In addition, Brodehl et al 5 performed exome sequencing in 2 families with several RCM patients and found 2 missense FLNC variants (p.S1624L and p.I2160F) that segregated with the disease and demonstrated the presence of cytoplasmic aggregates in heart tissue from RCM patients with p.S1624L. They also found that p.I2160F (localized in exon 39) showed fully familial segregation with the disease but did not form aggregates, suggesting that not all the FLNC variants exhibit the same pathomechanism. In this regard, mechanisms of protein aggregation, gain of function, and haploinsufficiency have been reported for the FLNC variants associated with myofibrillar myopathy. 12 Indeed, comprehensive functional studies are needed to undercover the FLNC mechanism that leads to the development of HCM and other cardiomyopathies, beyond the protein aggregation studies already reported.
In conclusion, we report the first large-scale screening of FLNC in HCM. Based on population, bioinformatic, functional, and familial segregation studies, we conclude that FLNC variants are likely associated with the development of HCM. The candidate variants were associated with mild forms of HCM and a reduced penetrance, making difficult their final classification as pathogenic and limiting their clinical usefulness. 
